{
  "$schema": "https://cdes.acidni.net/schemas/cannabinoid-therapeutics.json",
  "version": "1.0.0",
  "lastUpdated": "2026-01-27",
  "disclaimer": "This data is for informational purposes only and is not medical advice. Consult a healthcare provider before using cannabis for medical purposes.",
  "evidenceLevels": {
    "anecdotal": "Based on user reports and traditional use",
    "preliminary": "Early-stage research, animal studies, or in-vitro studies",
    "clinical": "Human clinical trials with published results",
    "established": "FDA-approved or multiple systematic reviews"
  },
  "therapeutics": [
    {
      "cannabinoidId": "cannabinoid:thc",
      "name": "THC",
      "fullName": "Delta-9-Tetrahydrocannabinol",
      "schedule": "Schedule I (federally), varies by state",
      "conditions": [
        {
          "condition": "Chemotherapy-Induced Nausea",
          "icdCode": "R11.0",
          "mechanism": "CB1 receptor activation in brainstem",
          "strength": "strong",
          "evidence": "established",
          "fdaApproved": true,
          "citations": [
            {
              "pmid": "18025276",
              "title": "Cannabinoids for control of chemotherapy induced nausea",
              "journal": "Cochrane Database of Systematic Reviews",
              "year": 2007
            }
          ]
        },
        {
          "condition": "HIV/AIDS Wasting Syndrome",
          "icdCode": "B22.2",
          "mechanism": "Appetite stimulation via CB1",
          "strength": "strong",
          "evidence": "established",
          "fdaApproved": true,
          "citations": [
            {
              "pmid": "7655456",
              "title": "Dronabinol for AIDS-related anorexia",
              "journal": "Annals of Internal Medicine",
              "year": 1995
            }
          ]
        },
        {
          "condition": "Chronic Pain",
          "icdCode": "G89.29",
          "mechanism": "Modulation of pain pathways via CB1/CB2",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "25635955",
              "title": "Cannabinoids for chronic non-cancer pain",
              "journal": "BMJ",
              "year": 2015
            }
          ]
        },
        {
          "condition": "Multiple Sclerosis Spasticity",
          "icdCode": "G35",
          "mechanism": "Muscle relaxation via CB1",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "22791906",
              "title": "Nabiximols for MS spasticity",
              "journal": "European Journal of Neurology",
              "year": 2012
            }
          ]
        },
        {
          "condition": "Glaucoma",
          "icdCode": "H40.9",
          "mechanism": "Reduces intraocular pressure",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": []
        },
        {
          "condition": "PTSD",
          "icdCode": "F43.1",
          "mechanism": "Modulates fear memory consolidation",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "24830188",
              "title": "Cannabis for PTSD symptoms",
              "journal": "Journal of Psychoactive Drugs",
              "year": 2014
            }
          ]
        }
      ],
      "symptoms": [
        {"symptom": "Nausea", "relevance": "high"},
        {"symptom": "Vomiting", "relevance": "high"},
        {"symptom": "Loss of appetite", "relevance": "high"},
        {"symptom": "Chronic pain", "relevance": "high"},
        {"symptom": "Muscle spasms", "relevance": "moderate"},
        {"symptom": "Nightmares (PTSD)", "relevance": "moderate"},
        {"symptom": "Insomnia", "relevance": "moderate"}
      ],
      "contraindications": [
        "History of psychosis or schizophrenia",
        "Pregnancy and breastfeeding",
        "Cardiovascular disease (tachycardia risk)",
        "Adolescents under 25 (brain development)",
        "History of substance use disorder"
      ],
      "sideEffects": [
        "Impaired memory and cognition",
        "Anxiety or paranoia (dose-dependent)",
        "Dry mouth",
        "Increased heart rate",
        "Coordination impairment"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:cbd",
      "name": "CBD",
      "fullName": "Cannabidiol",
      "schedule": "Schedule V (Epidiolex), otherwise unscheduled (<0.3% THC)",
      "conditions": [
        {
          "condition": "Epilepsy (Dravet/Lennox-Gastaut)",
          "icdCode": "G40.4",
          "mechanism": "Modulates sodium channels, reduces neuronal excitability",
          "strength": "strong",
          "evidence": "established",
          "fdaApproved": true,
          "citations": [
            {
              "pmid": "28538134",
              "title": "Trial of Cannabidiol for Drug-Resistant Seizures in Dravet Syndrome",
              "journal": "New England Journal of Medicine",
              "year": 2017
            }
          ]
        },
        {
          "condition": "Anxiety Disorders",
          "icdCode": "F41.9",
          "mechanism": "5-HT1A agonism, ECS modulation",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "30624194",
              "title": "Cannabidiol in Anxiety and Sleep",
              "journal": "The Permanente Journal",
              "year": 2019
            }
          ]
        },
        {
          "condition": "Chronic Pain",
          "icdCode": "G89.29",
          "mechanism": "Anti-inflammatory, TRPV1 modulation",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": []
        },
        {
          "condition": "Insomnia",
          "icdCode": "G47.0",
          "mechanism": "Anxiolytic effects improve sleep onset",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "30624194",
              "title": "Cannabidiol in Anxiety and Sleep",
              "journal": "The Permanente Journal",
              "year": 2019
            }
          ]
        },
        {
          "condition": "Inflammatory Conditions",
          "icdCode": "R09.89",
          "mechanism": "Inhibits cytokine production",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        }
      ],
      "symptoms": [
        {"symptom": "Seizures", "relevance": "high"},
        {"symptom": "Anxiety", "relevance": "high"},
        {"symptom": "Sleep difficulties", "relevance": "high"},
        {"symptom": "Chronic pain", "relevance": "moderate"},
        {"symptom": "Inflammation", "relevance": "moderate"},
        {"symptom": "Stress", "relevance": "moderate"}
      ],
      "contraindications": [
        "Liver disease (requires monitoring)",
        "Drug interactions (CYP450 inhibitor)",
        "Pregnancy (insufficient data)"
      ],
      "sideEffects": [
        "Fatigue",
        "Diarrhea",
        "Changes in appetite",
        "Elevated liver enzymes (high doses)"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:cbg",
      "name": "CBG",
      "fullName": "Cannabigerol",
      "schedule": "Unscheduled",
      "conditions": [
        {
          "condition": "Inflammatory Bowel Disease",
          "icdCode": "K51.9",
          "mechanism": "Reduces intestinal inflammation",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "23415610",
              "title": "Beneficial effect of CBG on experimental IBD",
              "journal": "Biochemical Pharmacology",
              "year": 2013
            }
          ]
        },
        {
          "condition": "Glaucoma",
          "icdCode": "H40.9",
          "mechanism": "Reduces intraocular pressure",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        },
        {
          "condition": "Huntington's Disease",
          "icdCode": "G10",
          "mechanism": "Neuroprotective",
          "strength": "weak",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "25252936",
              "title": "CBG neuroprotective effects",
              "journal": "Neurotherapeutics",
              "year": 2015
            }
          ]
        },
        {
          "condition": "Bacterial Infections (MRSA)",
          "icdCode": "A49.02",
          "mechanism": "Disrupts bacterial membranes",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "18681481",
              "title": "Antibacterial cannabinoids from Cannabis sativa",
              "journal": "Journal of Natural Products",
              "year": 2008
            }
          ]
        }
      ],
      "symptoms": [
        {"symptom": "Digestive inflammation", "relevance": "high"},
        {"symptom": "Eye pressure", "relevance": "moderate"},
        {"symptom": "Bacterial infection", "relevance": "moderate"}
      ],
      "contraindications": [
        "Limited safety data available",
        "Potential drug interactions"
      ],
      "sideEffects": [
        "Generally well-tolerated",
        "Dry mouth",
        "Drowsiness at high doses"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:cbn",
      "name": "CBN",
      "fullName": "Cannabinol",
      "schedule": "Unscheduled",
      "conditions": [
        {
          "condition": "Insomnia",
          "icdCode": "G47.0",
          "mechanism": "Mild sedative (THC degradation product)",
          "strength": "moderate",
          "evidence": "anecdotal",
          "fdaApproved": false,
          "citations": []
        },
        {
          "condition": "Pain",
          "icdCode": "G89.29",
          "mechanism": "Weak CB1/CB2 agonist",
          "strength": "weak",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        },
        {
          "condition": "ALS (Amyotrophic Lateral Sclerosis)",
          "icdCode": "G12.21",
          "mechanism": "Delays disease onset in models",
          "strength": "weak",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "16183560",
              "title": "CBN delays ALS in SOD1 mice",
              "journal": "Journal of Neurochemistry",
              "year": 2005
            }
          ]
        }
      ],
      "symptoms": [
        {"symptom": "Difficulty sleeping", "relevance": "high"},
        {"symptom": "Restlessness", "relevance": "moderate"},
        {"symptom": "Mild pain", "relevance": "moderate"}
      ],
      "contraindications": [
        "May enhance sedative medications",
        "Limited research on long-term use"
      ],
      "sideEffects": [
        "Drowsiness",
        "Mild sedation"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:cbc",
      "name": "CBC",
      "fullName": "Cannabichromene",
      "schedule": "Unscheduled",
      "conditions": [
        {
          "condition": "Depression",
          "icdCode": "F32.9",
          "mechanism": "Enhances anandamide availability",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "20332000",
              "title": "Antidepressant-like effect of CBC",
              "journal": "Pharmacology Biochemistry and Behavior",
              "year": 2010
            }
          ]
        },
        {
          "condition": "Acne",
          "icdCode": "L70.0",
          "mechanism": "Inhibits sebum production",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "27094344",
              "title": "Cannabinoids for sebaceous gland conditions",
              "journal": "Experimental Dermatology",
              "year": 2016
            }
          ]
        },
        {
          "condition": "Pain",
          "icdCode": "G89.29",
          "mechanism": "TRPV1 and TRPA1 activation",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        }
      ],
      "symptoms": [
        {"symptom": "Low mood", "relevance": "moderate"},
        {"symptom": "Skin inflammation", "relevance": "moderate"},
        {"symptom": "Pain", "relevance": "moderate"}
      ],
      "contraindications": [
        "Very limited human research",
        "Potential drug interactions unknown"
      ],
      "sideEffects": [
        "Generally well-tolerated in animal studies"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:thcv",
      "name": "THCV",
      "fullName": "Tetrahydrocannabivarin",
      "schedule": "Varies by jurisdiction",
      "conditions": [
        {
          "condition": "Obesity/Metabolic Syndrome",
          "icdCode": "E66.9",
          "mechanism": "CB1 antagonist at low doses, appetite suppressant",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "23359152",
              "title": "THCV for obesity and diabetes",
              "journal": "Nutrition & Diabetes",
              "year": 2013
            }
          ]
        },
        {
          "condition": "Type 2 Diabetes",
          "icdCode": "E11.9",
          "mechanism": "Improves glycemic control",
          "strength": "moderate",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "27573936",
              "title": "THCV and CBD in Type 2 Diabetes",
              "journal": "Diabetes Care",
              "year": 2016
            }
          ]
        },
        {
          "condition": "Parkinson's Disease",
          "icdCode": "G20",
          "mechanism": "CB2 agonist, neuroprotective",
          "strength": "weak",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "21323909",
              "title": "THCV antioxidant properties in Parkinson's",
              "journal": "British Journal of Pharmacology",
              "year": 2011
            }
          ]
        }
      ],
      "symptoms": [
        {"symptom": "Excessive appetite", "relevance": "high"},
        {"symptom": "Blood sugar instability", "relevance": "high"},
        {"symptom": "Tremors", "relevance": "moderate"},
        {"symptom": "Fatigue", "relevance": "moderate"}
      ],
      "contraindications": [
        "May be intoxicating at high doses",
        "Limited long-term safety data"
      ],
      "sideEffects": [
        "Shorter-duration psychoactivity than THC",
        "Generally well-tolerated"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:cbda",
      "name": "CBDA",
      "fullName": "Cannabidiolic Acid",
      "schedule": "Unscheduled",
      "conditions": [
        {
          "condition": "Nausea and Vomiting",
          "icdCode": "R11.2",
          "mechanism": "5-HT1A agonist (more potent than CBD)",
          "strength": "strong",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "23890879",
              "title": "CBDA suppresses nausea and vomiting",
              "journal": "British Journal of Pharmacology",
              "year": 2013
            }
          ]
        },
        {
          "condition": "Inflammation",
          "icdCode": "R09.89",
          "mechanism": "COX-2 selective inhibition",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "18556441",
              "title": "CBDA as selective COX-2 inhibitor",
              "journal": "Drug Metabolism and Disposition",
              "year": 2008
            }
          ]
        },
        {
          "condition": "Anxiety",
          "icdCode": "F41.9",
          "mechanism": "Enhanced 5-HT1A affinity vs CBD",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        }
      ],
      "symptoms": [
        {"symptom": "Nausea", "relevance": "high"},
        {"symptom": "Vomiting", "relevance": "high"},
        {"symptom": "Anticipatory nausea", "relevance": "high"},
        {"symptom": "Inflammation", "relevance": "moderate"}
      ],
      "contraindications": [
        "Heat-sensitive (decarboxylates to CBD)",
        "Limited human research"
      ],
      "sideEffects": [
        "Similar to CBD profile",
        "Generally well-tolerated"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:thca",
      "name": "THCA",
      "fullName": "Tetrahydrocannabinolic Acid",
      "schedule": "Varies by jurisdiction (non-psychoactive)",
      "conditions": [
        {
          "condition": "Nausea",
          "icdCode": "R11.0",
          "mechanism": "Antiemetic via 5-HT receptors",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "23889354",
              "title": "THCA antiemetic effects",
              "journal": "British Journal of Pharmacology",
              "year": 2013
            }
          ]
        },
        {
          "condition": "Neurodegenerative Diseases",
          "icdCode": "G31.9",
          "mechanism": "Neuroprotective, PPARγ activation",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "28853159",
              "title": "THCA in Huntington's and Parkinson's models",
              "journal": "British Journal of Pharmacology",
              "year": 2017
            }
          ]
        },
        {
          "condition": "Inflammation",
          "icdCode": "R09.89",
          "mechanism": "COX-1 and COX-2 inhibition",
          "strength": "moderate",
          "evidence": "preliminary",
          "fdaApproved": false,
          "citations": []
        }
      ],
      "symptoms": [
        {"symptom": "Nausea", "relevance": "high"},
        {"symptom": "Inflammation", "relevance": "moderate"},
        {"symptom": "Muscle spasms", "relevance": "moderate"}
      ],
      "contraindications": [
        "Heat converts to THC (becomes psychoactive)",
        "Raw cannabis only"
      ],
      "sideEffects": [
        "Non-psychoactive in raw form",
        "Generally well-tolerated"
      ]
    },
    {
      "cannabinoidId": "cannabinoid:delta8thc",
      "name": "Delta-8-THC",
      "fullName": "Delta-8-Tetrahydrocannabinol",
      "schedule": "Federally unclear, state-dependent",
      "conditions": [
        {
          "condition": "Nausea (Pediatric Cancer)",
          "icdCode": "R11.0",
          "mechanism": "CB1 agonist, antiemetic",
          "strength": "strong",
          "evidence": "clinical",
          "fdaApproved": false,
          "citations": [
            {
              "pmid": "7776837",
              "title": "Delta-8-THC for pediatric chemotherapy nausea",
              "journal": "Life Sciences",
              "year": 1995
            }
          ]
        },
        {
          "condition": "Anxiety",
          "icdCode": "F41.9",
          "mechanism": "Lower anxiety profile than D9-THC",
          "strength": "moderate",
          "evidence": "anecdotal",
          "fdaApproved": false,
          "citations": []
        }
      ],
      "symptoms": [
        {"symptom": "Nausea", "relevance": "high"},
        {"symptom": "Vomiting", "relevance": "high"},
        {"symptom": "Mild anxiety", "relevance": "moderate"}
      ],
      "contraindications": [
        "Similar to Delta-9-THC",
        "Quality concerns with synthesized products",
        "May still cause impairment"
      ],
      "sideEffects": [
        "Similar to D9-THC but milder",
        "Cognitive impairment",
        "Dry mouth"
      ]
    }
  ]
}
